摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(1-氨基-6-磺基萘-2-基氧基)乙酸 | 6373-39-3

中文名称
2-(1-氨基-6-磺基萘-2-基氧基)乙酸
中文别名
——
英文名称
[(1-Amino-6-sulfonaphthalen-2-yl)oxy]acetic acid
英文别名
2-(1-amino-6-sulfonaphthalen-2-yl)oxyacetic acid
2-(1-氨基-6-磺基萘-2-基氧基)乙酸化学式
CAS
6373-39-3
化学式
C12H11NO6S
mdl
——
分子量
297.29
InChiKey
XCOGAYHBZJLDOC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    20
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    135
  • 氢给体数:
    3
  • 氢受体数:
    7

安全信息

  • 海关编码:
    2922509090

文献信息

  • o-Aminoazoverbindungen
    申请人:BAYER AG
    公开号:EP0474039B1
    公开(公告)日:1994-11-09
  • TETRAKISAZO DYES, THEIR PRODUCTION AND USE
    申请人:Clariant Finance (BVI) Limited
    公开号:EP0931109B1
    公开(公告)日:2003-02-26
  • Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same
    申请人:Shapiro Robert
    公开号:US20070032418A1
    公开(公告)日:2007-02-08
    Lead compounds were obtained in a high throughput screen (HTS) of angiogenin (ANG; a potent inducer of angiogenesis) enzyme activity, an RNase. One lead was shown to delay appearance of tumors in an animal tumor system, and to reduce the number of animals having tumors. Several lead compound analogs were found to be even more potent inhibitors of ANG activity compared to the original leads, and two were also found to have greater affinity for ANG than for pancreatic RNase. Other embodiments disclose a method comprising obtaining a ribonuclease inhibitor and a composition; and admixing the ribonuclease inhibitor and the composition to form an admixture, wherein a ribonuclease that may be present in the admixture is inhibited.
  • Assays for identification of topoisomerase inhibitors
    申请人:Stivers T. James
    公开号:US20080020973A1
    公开(公告)日:2008-01-24
    The instant invention provides a continuous spectroscopic assay for DNA topoisomerase activity. The invention further provides topoisomerase inhibitors and pharmaceutical compositions for the treatment of topoisomerase associated diseases and disorders.
  • US5183881A
    申请人:——
    公开号:US5183881A
    公开(公告)日:1993-02-02
查看更多